SCHEMBL2487182

SCHEMBL2487182

CC1(C)OB(c2cnc(Cl)nc2OCc2ccccc2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.49
DGAT1 O75907 1/20 0.46
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CNR1 P21554 1/20 0.36
ACHE P22303 1/20 0.36
CNR2 P34972 1/20 0.36
SLC6A4 P31645 2/20 0.36
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
PDE5A O76074 1/20 0.34
KDM4E B2RXH2 1/20 0.34
DAPK1 P53355 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25935368 0.86 DGAT1 (0.47) PIN1DGAT1NR1H2NR1H3L3MBTL1
SCHEMBL24978007 0.86 DGAT1 (0.47) PIN1DGAT1NR1H2NR1H3L3MBTL1
SCHEMBL25482311 0.80 DGAT1 (0.46) DGAT1NR1H2NR1H3L3MBTL1HPGD
SCHEMBL29532520 0.80 DGAT1 (0.46) DGAT1NR1H2NR1H3L3MBTL1HPGD
SCHEMBL19585801 0.80 DGAT1 (0.46) DGAT1NR1H2NR1H3L3MBTL1HPGD
SCHEMBL24825212 0.78 DGAT1 (0.43) PIN1DGAT1NR1H2NR1H3L3MBTL1
SCHEMBL1360465 0.76 DGAT1 (0.47) DGAT1NR1H2NR1H3L3MBTL1CNR1
SCHEMBL23070575 0.76 DGAT1 (0.45) DGAT1NR1H2NR1H3L3MBTL1CNR1
SCHEMBL25447041 0.74 DGAT1 (0.43) DGAT1NR1H2NR1H3L3MBTL1HPGD
SCHEMBL9987642 0.74 PIN1 (0.59) PIN1L3MBTL1CNR1ACHECNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 PIN1 4004/4885DGAT1 2605/4885NR1H2 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.